LON:ABZA - Abzena Stock Price, Price Target & More

GBX 19 0.00 (0.00 %)
(As of 04/24/2018 04:00 PM ET)
Previous CloseGBX 19
Today's RangeGBX 18.30 - GBX 19.76
52-Week RangeGBX 24.50 - GBX 53
Volume23,490 shs
Average Volume26,706 shs
Market Capitalization£50.91 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Abzena (LON:ABZA)

Abzena logoAbzena plc engages in the provision of services and technologies for the development and commercialization of biopharmaceutical products in North America, Europe, the United Kingdom, and internationally. It provides antibody drug conjugate linker, antibody humanization, and protein deimmunisation technologies and solutions, which include phage display, Hybridoma sequencing, and developability assessment solutions for the discovery, isolation, development, and selection of antibodies; immunogenicity assessment and custom assays, as well as Cytokine Screen, an in vitro assay to evaluate the risk of biopharmaceutical products causing cytokine release syndrome prior to its test in clinical trials; antibody and protein engineering solutions, which cover Ig class and isotype switching, antibody reformatting and humanization, protein deimmunisation, affinity maturation, antibody and protein production, and bioassays and bioanalytics; and antibody drug conjugates, such as cysteine and lysine conjugation solutions, as well as ThioBridge, a disulfide rebridging linker. The company also provides solutions in the area of bioassays, which cover drug-conjugate and payload characterization, binding and competition assays, cell health assays, functional assays, Fc binding and function assays, and bespoke assay development; bioanalytics that cover candidate selection, biosimilarity, protein and peptide identification, ADC characterization, and analytical method development; mammalian manufacturing; peptide synthesis, modifications, and analytics; bioconjugate and antibody drug conjugate manufacturing; and chemical synthesis. It serves biopharmaceutical research and development industry. Abzena plc has a co-development agreement with Enleofen Bio Pte Ltd. to develop antibody therapeutics for the treatment of fibrotic human diseases. The company was incorporated in 2014 and is headquartered in Cambridge, the United Kingdom.

Receive ABZA News and Ratings via Email

Sign-up to receive the latest news and ratings for ABZA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:ABZA
CUSIPN/A
Phone+44-1223-903498

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-83.31%
Return on Equity-36.99%
Return on Assets-30.72%

Miscellaneous

EmployeesN/A
Outstanding Shares213,820,000

How to Become a New Pot Stock Millionaire

Abzena (LON:ABZA) Frequently Asked Questions

What is Abzena's stock symbol?

Abzena trades on the London Stock Exchange (LON) under the ticker symbol "ABZA."

What price target have analysts set for ABZA?

3 analysts have issued 12-month price targets for Abzena's shares. Their predictions range from GBX 42 to GBX 70. On average, they expect Abzena's share price to reach GBX 58 in the next year. View Analyst Ratings for Abzena.

Who are some of Abzena's key competitors?

Who are Abzena's key executives?

Abzena's management team includes the folowing people:
  • Dr. William John Edward Burt DPhil, Chief Exec. Officer & Exec. Director (Age 50)
  • Mr. Julian Mathew Smith, CFO, Company Sec. & Exec. Director (Age 53)
  • Prof. Sunil Shaunak M.D., Ph.D., Co-Founder and Chairman of the Scientific Advisory Board
  • Dr. Antony Godwin Ph.D., Co-Founder
  • Prof. Steve Brocchini Ph.D., Co-Founder

Has Abzena been receiving favorable news coverage?

Media coverage about ABZA stock has been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Abzena earned a coverage optimism score of 0.24 on Accern's scale. They also gave news articles about the company an impact score of 46.05 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Abzena?

Shares of ABZA and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Abzena's stock price today?

One share of ABZA stock can currently be purchased for approximately GBX 19.

How big of a company is Abzena?

Abzena has a market capitalization of £50.91 million.

How can I contact Abzena?

Abzena's mailing address is Babraham Hall, Babraham Research, CAMBRIDGE, CB22 3AT, United Kingdom. The company can be reached via phone at +44-1223-903498.


MarketBeat Community Rating for Abzena (ABZA)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  135 (Vote Outperform)
Underperform Votes:  88 (Vote Underperform)
Total Votes:  223
MarketBeat's community ratings are surveys of what our community members think about Abzena and other stocks. Vote "Outperform" if you believe ABZA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABZA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Abzena (LON:ABZA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Abzena in the last 12 months. Their average twelve-month price target is GBX 58The high price target for ABZA is GBX 70 and the low price target for ABZA is GBX 42. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 58GBX 64GBX 75GBX 75

Abzena (LON:ABZA) Consensus Price Target History

Price Target History for Abzena (LON:ABZA)

Abzena (LON:ABZA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
4/16/2018Numis SecuritiesReiterated RatingBuyGBX 80 -> GBX 62View Rating Details
4/16/2018Peel HuntReiterated RatingBuyGBX 42View Rating Details
12/11/2017FinnCapReiterated RatingBuyGBX 70View Rating Details
4/26/2017N+1 SingerReiterated RatingCorporateView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Dividends

Abzena (LON:ABZA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Abzena (LON ABZA) Insider Trading and Institutional Ownership History

Insider Trading History for Abzena (LON:ABZA)

Abzena (LON ABZA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Abzena (LON ABZA) News Headlines

Source:
DateHeadline
Numis Securities Reiterates "Buy" Rating for Abzena (ABZA)Numis Securities Reiterates "Buy" Rating for Abzena (ABZA)
www.americanbankingnews.com - April 19 at 4:34 PM
Abzena (ABZA) Stock Rating Reaffirmed by Peel HuntAbzena (ABZA) Stock Rating Reaffirmed by Peel Hunt
www.americanbankingnews.com - April 16 at 7:06 AM
Numis Securities Lowers Abzena (ABZA) Price Target to GBX 62Numis Securities Lowers Abzena (ABZA) Price Target to GBX 62
www.americanbankingnews.com - April 16 at 7:00 AM
With A -28.65% Earnings Drop, Did Abzena plc (LON:ABZA) Really Underperform?With A -28.65% Earnings Drop, Did Abzena plc (LON:ABZA) Really Underperform?
finance.yahoo.com - April 11 at 11:05 AM
Peel Hunt Reaffirms Buy Rating for Abzena (ABZA)Peel Hunt Reaffirms Buy Rating for Abzena (ABZA)
www.americanbankingnews.com - April 10 at 8:27 AM
FinnCap Reiterates Buy Rating for Abzena (ABZA)FinnCap Reiterates Buy Rating for Abzena (ABZA)
www.americanbankingnews.com - April 9 at 7:30 PM
Abzenas (ABZA) "Buy" Rating Reiterated at Peel HuntAbzena's (ABZA) "Buy" Rating Reiterated at Peel Hunt
www.americanbankingnews.com - April 4 at 12:31 PM
Peel Hunt Reaffirms "Buy" Rating for Abzena (ABZA)Peel Hunt Reaffirms "Buy" Rating for Abzena (ABZA)
www.americanbankingnews.com - March 27 at 8:44 AM
Facility Remodelling Completed for Abzena’s New Antibody-Drug Conjugate GMP Manufacturing SuiteFacility Remodelling Completed for Abzena’s New Antibody-Drug Conjugate GMP Manufacturing Suite
finance.yahoo.com - March 26 at 10:58 AM
Is It The Right Time To Buy Abzena plc (LON:ABZA)?Is It The Right Time To Buy Abzena plc (LON:ABZA)?
finance.yahoo.com - March 26 at 10:58 AM
When Will Abzena plc (LON:ABZA) Breakeven?When Will Abzena plc (LON:ABZA) Breakeven?
finance.yahoo.com - March 19 at 10:36 AM
Abzena (ABZA) Rating Reiterated by Peel HuntAbzena (ABZA) Rating Reiterated by Peel Hunt
www.americanbankingnews.com - March 5 at 12:58 PM
Is Abzena plc’s (LON:ABZA) Balance Sheet Strong Enough To Weather A Storm?Is Abzena plc’s (LON:ABZA) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - February 12 at 8:27 AM
Abzena (ABZA) Research Coverage Started at Peel HuntAbzena (ABZA) Research Coverage Started at Peel Hunt
www.americanbankingnews.com - February 11 at 8:06 PM
Abzena (ABZA) Rating Reiterated by FinnCapAbzena (ABZA) Rating Reiterated by FinnCap
www.americanbankingnews.com - December 25 at 2:14 PM
Abzena Plc :ABZA-GB: Earnings Analysis: For the six months ended September 30, 2017 : December 14, 2017Abzena Plc :ABZA-GB: Earnings Analysis: For the six months ended September 30, 2017 : December 14, 2017
finance.yahoo.com - December 15 at 11:27 AM
Where Abzena plc (LON:ABZA) Stands In Terms Of Earnings Growth Against Its IndustryWhere Abzena plc (LON:ABZA) Stands In Terms Of Earnings Growth Against Its Industry
finance.yahoo.com - December 14 at 11:09 AM
Numis Securities Reaffirms Buy Rating for Abzena (ABZA)Numis Securities Reaffirms Buy Rating for Abzena (ABZA)
www.americanbankingnews.com - December 13 at 6:46 AM
FinnCap Reaffirms Buy Rating for Abzena PLC (ABZA)FinnCap Reaffirms Buy Rating for Abzena PLC (ABZA)
www.americanbankingnews.com - November 23 at 10:40 PM
At £0.3225, Is Abzena plc (AIM:ABZA) A Buy?At £0.3225, Is Abzena plc (AIM:ABZA) A Buy?
finance.yahoo.com - November 21 at 3:59 PM
Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, with Support from Abzena, Featured in ‘Nature ...Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, with Support from Abzena, Featured in ‘Nature ...
www.businesswire.com - November 14 at 8:41 PM
Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by ... - Business Wire (press release)Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by ... - Business Wire (press release)
www.businesswire.com - November 14 at 3:39 PM
Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, with Support from Abzena, Featured in ‘Nature’ ArticleNovel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, with Support from Abzena, Featured in ‘Nature’ Article
finance.yahoo.com - November 14 at 3:39 PM
Abzena and UGA Biopharma Partner to Develop a Cell Line Expressing a Biosimilar Therapeutic for Multiple Sclerosis - Business Wire (press release)Abzena and UGA Biopharma Partner to Develop a Cell Line Expressing a Biosimilar Therapeutic for Multiple Sclerosis - Business Wire (press release)
www.businesswire.com - October 20 at 8:35 PM
Abzena and UGA Biopharma Partner to Develop a Cell Line Expressing a Biosimilar Therapeutic for Multiple SclerosisAbzena and UGA Biopharma Partner to Develop a Cell Line Expressing a Biosimilar Therapeutic for Multiple Sclerosis
finance.yahoo.com - October 19 at 3:31 PM
What Are The Drivers Of Abzena plc’s (AIM:ABZA) Risks?What Are The Drivers Of Abzena plc’s (AIM:ABZA) Risks?
finance.yahoo.com - October 6 at 3:44 PM
Abzena PLC (ABZA) PT Lowered to GBX 70Abzena PLC (ABZA) PT Lowered to GBX 70
www.americanbankingnews.com - September 23 at 12:52 AM
Abzena PLCs (ABZA) Under Review Rating Reaffirmed at FinnCapAbzena PLC's (ABZA) Under Review Rating Reaffirmed at FinnCap
www.americanbankingnews.com - September 17 at 12:58 AM
Abzena PLCs (ABZA) Buy Rating Reaffirmed at Numis Securities LtdAbzena PLC's (ABZA) Buy Rating Reaffirmed at Numis Securities Ltd
www.americanbankingnews.com - September 16 at 11:02 PM
Abzena PLC (ABZA) Stock Rating Reaffirmed by FinnCapAbzena PLC (ABZA) Stock Rating Reaffirmed by FinnCap
www.americanbankingnews.com - August 28 at 5:02 PM
Abzena and Telix Sign Licence Agreement for Abzena’s Prostate-Specific Membrane Antigen AntibodiesAbzena and Telix Sign Licence Agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies
finance.yahoo.com - July 18 at 3:36 PM
Abzena and OBI Pharma Sign ThioBridge™ Licence Agreement - Business Wire (press release)Abzena and OBI Pharma Sign ThioBridge™ Licence Agreement - Business Wire (press release)
www.businesswire.com - July 13 at 8:47 PM
Abzena and OBI Pharma Sign ThioBridge™ Licence AgreementAbzena and OBI Pharma Sign ThioBridge™ Licence Agreement
finance.yahoo.com - July 11 at 4:25 PM
Annual Report and Accounts - London South East (registration) (blog)Annual Report and Accounts - London South East (registration) (blog)
www.lse.co.uk - June 20 at 1:25 AM
Blocklisting update - London South East (registration) (blog)Blocklisting update - London South East (registration) (blog)
www.lse.co.uk - January 11 at 1:30 AM
Half Year 2017 Abzena PLC Earnings Release - Time Not SuppliedHalf Year 2017 Abzena PLC Earnings Release - Time Not Supplied
biz.yahoo.com - November 30 at 11:05 AM

SEC Filings

Abzena (LON:ABZA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Abzena (LON ABZA) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.